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Abstract—Recent developments in the field of gene sequenc-
ing technology greatly accelerated discovery of mutations that
cause various genetic disorders. At the same time, a typical
sequencing experiment generates a large number of candidate
mutations, hence detecting single or few causative variants is
still a formidable problem. Many computational methods have
been proposed to assist this process, from which a large portion
employ statistical learning in some form. Consequently, each
newly designed algorithm is routinely compared to other compet-
ing systems in hope to demonstrate advantageous performance.
In this work we review and discuss several issues related to
the current practice of evaluation of mutation prioritization
algorithms and suggest possible directions for improvements.
I. INTRODUCTION
The advent of high-throughput technologies, such as
the next generation sequencing, has significantly accelerated
biomedical research by enabling large portions of human
genome to be simultaneously scanned. This ability facilitates
the discovery of various alterations at a molecular level and
has made high-throughput technologies an irreplaceable tool
for studying complex [1], [2] and Mendelian diseases [3].
A typical sequencing study would compare the genomes of
patients affected by certain condition to genomes of healthy
individuals (e.g. unaffected family members, healthy popula-
tion cohorts) to detect genes carrying a burden of pathogenic
mutations [4]–[6]. However, each human genome harbors
approximately 3.7 million single nucleotide variants (SNVs)
[7] of which the vast majority are putatively neutral (i.e.,
they do not alter the fitness of their carrier) [8]. Given the
prohibitive costs of confirmatory experiments (e.g. engineering
CRISPR/CAS9 animal models), it is impossible to functionally
validate all detected variants.
Moreover, given our current poor functional understanding
of non-protein coding regions, it is often cost-effective to limit
the experiment to the protein coding regions of the genome
(i.e. the exome). Limiting the scope to the exome reduces the
number of mutations found by roughly 3 orders of magnitude
(∼ 20000 coding variants per exome). By applying further
filtering and only retaining rare truncating loss-of-function
mutations and amino-acid altering mutations (nSNVs) we
can further reduce the search space for putatively pathogenic
variation to hundreds of mutations (∼ 500 rare protein-altering
mutations per exome) [9]. Even these reduced numbers of
mutations remains prohibitive for downstream studies and
further prioritization is needed.
To address this challenge, a number of computational
methods have been proposed to help discover disease-causing
mutations. Many of these methods use biochemical, evolu-
tionary or structural properties of the mutations under study
to calculate a score that reflects their potential deleteriousness
[10]–[16]. Some approaches combine multiple scores to obtain
more reliable estimates [17], [18], while others are part of
wider mutation prioritization frameworks that include various
filtering steps and other features [19], [20]. Finally, several
recent methods incorporate information about phenotypic rep-
resentations of a disease to increase the precision of a detection
[21], [22].
Many mutation prioritization algorithms employ learning,
either directly or indirectly. For example, eXtasy [21] uses
Random Forests [23] to model the complex relationship
between several phenotypic and genomic features and the
disease-causing potential of a mutation. In contrast, SIFT [10]
takes a more indirect approach and provides an alignment-
based score, thus generates a ”training set” for each new pre-
diction. Another example of indirect learning is the functional
impact score for amino acid residue changes from Mutation
Assessor [16] that is based on evolutionary conservation pat-
terns.
Regardless of whether learning is employed directly or
not, prioritization frameworks are evaluated on appropriate
use-cases in order to quantify their performance. This is a
crucial step, as it provides indication for their suitability in
practice. Despite its importance, the impact of the evaluation
methodology is less well understood and there is no accepted
standard for evaluation. This paper reviews the current practice
of evaluation of computational methods for mutation prioriti-
zation along several lines.
First, we discuss the choice of validation data set in terms
of its domain, composition and class distribution. We identify
limitations that are implicitly present in studies that use certain
types of evaluation data and propose modifications that can
help in overcoming these limitations.
Second, we analyze how various performance metrics are
currently used to benchmark approaches and advocate a slight
change of a perspective in this regard. Finally, we conclude the
overall discussion with a short overview of lessons-learned and
we outline possible directions of the further work.
II. EVALUATION DATA
When benchmarking prioritization systems, usually the
goal is to evaluate how well each system distinguishes between
mutations of interest (i.e., positive examples) and variants that
are not interesting (i.e., negative examples). While several
characteristics of the data are important in this regard, we
will focus on two aspects: (1) what constitutes a positive and
negative example, and (2) what is the ratio of positive to
negative examples.
A. Domain of a testing set
The umbrella term mutation prioritization in reality covers
wide variety of different algorithms that are designed with
different goals in mind. Some systems are trained to distinguish
neutral from deleterious variants, such as PolyPhen [24] or
CADD [20]. Deleterious variants affect function of a gene but
do not necessary cause a genetic disorder, even sometimes
one outcome is used as a proxy for another, either in training
or evaluation (ex. SIFT [10]). In contrast, some methods are
directly designed to distinguish disease-causing from neutral
mutations (ex. CAROL score [17]). Some algorithms are
further specialized in particular disease classes, such as rare
genetic disorders [21], [22] or cancer [16] (see Table I).
Mutation prioritization algorithms also differ in scope.
Some of them can process only one type of mutations,
while some are capable of dealing with various types. For
example, eXtasy works only on nSNVs [21], while Phen-
Gen can analyze start-loss, stop-gain and stop-loss variants,
small insertions and deletions in addition to nSNVs [22].
Furthermore, even the methods designed to address the same
goal and that have the same scope are sometimes trained (or
validated) on a fundamentally different composition of training
data. For instance, the Phen-Gen model for nonsynonymous
variants has been trained on data that include nonsynonymous
substitutions in the human reference genome with respect to
the ancestral sequence as controls, while eXtasy only uses rare
neutral variants as negative examples.
The heterogeneity of validation data used for mutation
prioritization gives rise to two types of evaluation problems.
First, algorithms designed for (slightly) different tasks are
compared to each other. Second, sometimes the data used
to validate an algorithm differs from the domain where the
algorithm will be used in practice.
One example of the first type of validation issue is the com-
mon practice of comparing methods for discovering disease-
causing mutations with methods that assess deleteriousness
of variants. Among the algorithms that we reviewed here,
Mutation Taster 2 [25], KGG-Seq [19] and eXtasy [21] are
all tested against SIFT [10] and PolyPhen2 [11] on a data
composed of disease-causing mutations and neutral variants.
This practice is problematic, as deleterioussnes of a variant
does not automatically imply that a variant is disease-causing.
In fact, it has been estimated that a genome of a healthy
individual harbors up to one hundred variants that severely
disrupt protein-coding genes [26].
An example of the second issue is the usage of common
polymorphisms as controls when training and testing an algo-
rithm for detection of disease-causing mutations, as in [16],
[25]. In practice, common polymorphisms are usually filtered
out before prioritization. Hence, when a validation data set is
composed in this way, it is unclear if an evaluated method
assesses the likelihood that a variant is disease-causing or it
implicitly only assesses the rarity of a variant. As the rarity
of a variant correlates with its likelihood of being involved
in a disorder, this type of evaluation could lead to misleading
results.
One of the basic assumptions of standard machine learning
approaches is that examples that constitute training data and
testing data are drawn independently from the same distribu-
tion [27], [28]. If this assumption is violated, an algorithm’s
performance may significantly decrease if applied to data
drawn from a distribution that substantially deviates from that
of a training data. Therefore, it is expected that methods tested
on inadequate data will preform poorly, especially compared
to the methods that have been tailored for use-case that this
data represents.
We acknowledge that it is not always possible to find
several algorithms that are designed to tackle exactly the same
facet of the mutation prioritization problem as an evaluated
method, which is the reason why often algorithms of slightly
different but related function are used as a substitute. However,
this limitation of study designs is not always clearly stated.
Finally, researchers should strive to ensure that the validation
data follows the distribution expected to be observed in prac-
tice.
B. Balance of a testing set
In addition to domain heterogeneity, evaluation data for
mutation prioritization algorithms also differ in terms of class
skew, which is the ratio of positive to negative examples. To
illustrate this fact, Table I provides the class distribution for
the data used to validate nine methods (SIFT [10], PolyPhen2
[11], PROVEAN [29], [30], CAROL [17], CONDEL [18],
eXtasy [21], Mutation Assessor [16], Mutation Taster 2 [25]
and VAAST [31]). Note that class skew varies significantly,
even when only considering this small subset of prioritization
algorithms. Concretely, for these data sets the class balance
ranges from approximately one and a half positive instance
TABLE I. ALGORITHM’S TARGET AND CLASS BALANCE OF TESTING
SETS USED FOR EVALUATION OF DIFFERENT MUTATION PRIORITIZATION
ALGORITHMS
Method Target variants Skew of the testing set(s)
SIFT deleterious 1.46, 0.51
PolyPhen2 deleterious 1.46, 0.50
PROVEAN deleterious 0.86, 0.63, 0.25, 0.86
CAROL deleterious 0.20
LRT deleterious real exomes
CONDEL deleterious 1.50, 0.50
eXtasy rare disease-causing 0.09, 0.56
Mutation Assessor cancer 0.54
Mutation Taster 2 disease-causing 1.00
VAAST disease-causing 1.00
per each negative instance (CONDEL), to eleven negative
instances per each positive instance (eXtasy). In many cases,
testing data contains approximately twice as much negatives
than positives.
The first problem with the class distribution of the data
typically used for evaluating mutation prioritization methods
is that it barely ever corresponds to the true distribution in
practice (even counterexamples exist, ex. LRT [13] is tested
on real exomes). Usually, a class distribution is much less
severe (i.e., closer to 1:1 ratio) in validation data than actual
data. For instance, a single exome harbors several thousands
of mutations, from which one or none is damaging. At the
same time, methods that are designed for exome analysis are
usually trained and tested on data with quite different balance
[21].
Consequently, is very difficult for a potential user to
anticipate how the algorithm will behave in practice, especially
if the expected class balance (i.e., prevalence) is not provided.
Moreover, this is not just a problem from the standpoint
of interpreting performance metrics, but also impacts model
selection. That is, different learning methods might be more
or less appropriate, given the severity of the class distribution
skew [32], [33]. It is not hard to envision that in many cases
methods tailored for outline detection might be more suitable
for dealing with extreme imbalance than classical classification
algorithms, yet they can be selected against during model
selection if tested on relatively balanced data.
Second, many performance metrics commonly used for
evaluating mutation prioritization algorithms are in fact sen-
sitive to changes in the class distribution. As an example,
consider accuracy. In principle, under two very different class
balances, several tested classifiers can be ranked differently
in terms of accuracy, depending on which class they are
“specialized in”. On the extreme end, using the accuracy to
compare two algorithms on a highly imbalanced data set can
misleadingly indicate that a trivial classifier (i.e., one that
assigns the same label to all tested instances) performs better
than less “accurate” one, while at the same time it is useless
for prediction.
Arguably, it is not always possible to obtain realistic data to
test novel algorithms. Nevertheless, the correct class balance
can be simulated if intended use-case for an algorithm has
been precisely defined beforehand. For example, to evaluate
exome-based prioritization a synthetic data can be created by
injecting disease-causing variant in a healthy exome, as done
in [19], [22]. Alternatively, the class distribution of a data set
can be artificially altered. That is, one class can be subsampled
to reflect a class balance that is expected under realistic usage
scenario, as done in [34]. Moreover, the later approach can
be easily combined with bootstrapping [35] to stabilize the
estimates of the performance metrics. Finally, if none of these
solutions can be easily implemented, then at least expected
prevalence should be provided such that class balance-sensitive
performance metrics can be calculated.
III. PERFORMANCE METRICS
In order to accurately quantify a system’s performance, it is
important to select appropriate evaluation metrics that provide
insight into how the system will perform in practice. In this
section we discuss currently dominant, classification-oriented
selection of performance metrics and suggest how a slight
change of perspective on the mutation prioritization problem
can facilitate better insight in future behavior of evaluated
algorithms.
A. Classification perspective
Most mutation prioritization algorithms are in fact clas-
sifiers by construction. They are designed and tuned to dis-
tinguish positive (deleterious, disease-causing) from negative
(neutral) cases, so hence provide scores or rankings only as
a by-product of the classification process. Due to how these
scores are derived, they seldom represent proper probabilities.
For example, CADD [20] combines 63 features (including
predictions from other algorithms, such as SIFT and PolyPhen)
using a support vector machine classifier (SVM [36]) with a
linear kernel. The score that CADD assigns to a variant is in
essence a combination of scaled distances from several SVM
decision hyperplanes and therefore it is not a probability.
Consequently, typical classification performance metrics
based on a confusion matrix are routinely reported in arti-
cles that describe novel methods. Figure 1 provides a non-
exhaustive list of basic metrics that can be derived from a
confusion matrix. To illustrate the de-facto evaluation culture,
Table II lists the reported performance measures for several
mutation prioritization methods, including SIFT (new version
[37]), PolyPhen2 [11], PROVEAN [29], [30], CAROL [17],
LRT [13], CONDEL [18], eXtasy [21], Mutation Assessor
[16], Mutation Taster 2 [25] and VAAST [31].
As is apparent from the Table II, estimates of accuracy,
sensitivity and specificity are most often provided. As an
alternative to accuracy, some authors report balanced accuracy.
In some cases, the false positive and false negative rates
(FPR and FNR) accompany the sensitivity and specificity.
Finally, the Matthews correlation coefficient (MCC) is also
occasionally reported on.
Because accuracy is an aggregate performance measure, it
is not very useful for describing performance of a prioritization
algorithm. Furthermore, as discussed in subsection II.B., care
needs to be taken when interpreting its value when there
is an extreme class imbalance, which is always the case
in practical disease-causing mutation discovery. In contrast,
balanced accuracy (i.e., mean of sensitivity and specificity)
does not suffer from this problem, but it assumes that it is
Fig. 1. Simple performance measures based on confusion matrix
TABLE II. PERFORMANCE METRICS REPORTED FOR DIFFERENT
MUTATION PRIORITIZATION ALGORITHMS
Method Performance metrics
SIFT Acc, Sens, Spec, Prec, NPV, MCC, ROC
PolyPhen2 Sens for fixed FPR values (0.10,0.15,..,0.8), ROC
PROVEAN bAcc, Sens, Spec, ROC, aROC
CAROL Acc, Sens, Spec, FPR, FNR, ROC, aROC
LRT Confusion matrix
CONDEL Acc, ROC
eXtasy Acc, Sens, Spec, Prec, NPV, MCC, ROC, aROC, PR, aPR
Mutation Assessor Acc, ROC, aROC, distributions of scores
Mutation Taster 2 Acc, Sens, Spec, Prec, NPV, ROC
VAAST Acc
Abbreviations : Acc (Accuracy), bAcc (Balanced accuracy), Sens (Sensitivity),
Spec (Specificity), Prec (Precision), NPV (Negative predictive value),
MCC (Matthews correlation coefficient), ROC (Receiver operating characteristic curve),
aROC (area under the ROC curve),FPR (False positive rate), FNR (False negative rate),
PR (Precision-recall curve), aPR (area under the PR curve)
equally important to correctly classify both positive and nega-
tive instances. Finally, FPR and FNR are just complements of
sensitivity and specificity, so they do not provide an additional
information about an algorithm’s performance if sensitivity and
specificity are given.
Receiver operating characteristic (ROC) curves, which
show how an algorithm performances under different operating
conditions, are also frequently provided. Surprisingly, the area
under the ROC curve (aROC) is not always reported together
with the graphical representation of the curve itself. The area
under the ROC curve is proportional to Wilcoxon statistics,
hence to probability of producing correct pairwise ranking
[38]. In other words, the aROC represents probability that
a randomly chosen positive example is ranked higher than a
randomly chosen negative example. This equivalence allows
estimating the average rank of positive instances, so it is
strongly advisable to include it with the ROC curve.
However, even the aROC should be interpreted with cau-
tion. First, it may be misleading to compare two algorithms
on the basis of this value alone as it is an aggregate measure
of different operating conditions. The graphic representation
is needed to ascertain under which operating ranges one
classifier outperforms another. For example, if two ROC curves
cross then it is possible that one curve has a larger value
of aROC even though the alternative may have much better
performance in the most important operating range. Second,
aROC implicitly assumes a different misclassification cost
distribution for each tested classifier, where this distribution
directly depend on scores provided by the classifier [39].
Hence, from the metrics discussed so far, it is useful to
provide sensitivity, specificity and the ROC curve together with
exact aROC when reporting the performance of a mutation
prioritization method. These measures provide information on
proportions of positive and negative examples that can be
captured by the algorithm for different decision thresholds.
Matthews correlation coefficient is performance metric that is
a bit less effective for this given purpose, as it does not have
simple and direct interpretation. That is, MCC is in essence
Pearson product-moment correlation coefficient calculated us-
ing the confusion matrix [40]. Nevertheless, all the measures
mentioned so far do not provide a complete information on
prioritization performance, for the reasons that we exemplify
in the next section.
B. Information retrieval perspective
In a typical application of a mutation prioritization algo-
rithm one rarely conducts confirmatory experiments on all
mutations that are classified as positive due to the high cost as-
sociated with the experimental verification. Therefore analyses
are more often performed starting from the top of prioritized
list of mutations, going downwards until genuine causative
variant is found. From this perspective mutation prioritization
is an instance of the information retrieval problem, rather than
a standard classification task.
Hence, conventional classification performance metrics,
such as sensitivity and specificity, do not capture all the impor-
tant behavior characteristics of an algorithm. For completeness,
this information should be supplemented with retrieval metrics,
such as precision and PR curve [41], [42]. To further illustrate
this issue we have constructed an artificial example that is
displayed in Figure 2. This example has been conveniently
created to emphasize the problem, yet it shares many typical
features of real mutation prioritization problems. In fact, these
features, such as the severe class imbalance, are even more
pronounced in realistic use-cases than here.
The panel A in Figure 2 displays a number of (neutral
and causative) mutations in a space that is spanned by the
two predictive features, together with a hypothetical classifi-
cation function. This classifier achieves decent sensitivity and
specificity (0.7 and 0.78, respectively), but it is practically
useless for prioritization due to a very low precision (0.11).
The precision value implies that on average nine experiments
have to be performed to find one causative variant. In contrast,
using the classifier with a different learning bias (panel B)
reduces this number to approximately four experiments, which
is not readily apparent from its sensitivity and specificity,
which are somewhat similar to the first approach (0.7 and
0.92, respectively). Moreover, the precision can not be even
calculated from sensitivity and specificity alone: it requires
knowing the prevalence.
The situation is further complicated when a ranking is in-
troduced. Panels C and D on Figure 2 depict multiple decision
boundaries for the two classifiers corresponding to various
scores (i.e., decision thresholds). Each decision boundary pro-
duces different values of sensitivity, specificity and precision,
which consequently results in a different point in ROC and
PR spaces (see panels E and F). Obviously, both ROC and PR
curves produced by the “square” classifier dominate over that
of “circle” classifier. However, examining ROC curves alone
might suggest that there is little difference between the two
methods.
In contrast, PR curves emphasize this difference, especially
in the vicinity of the highest ranks. For example, from the PR
curve of the ”square” classifier one can easily read that in
the limit one experiment is needed to find the first causative
mutation, five experiments to find the first three variants and
so on. In contrast, this information is not readily apparent
in the ROC curve. Hence, even though the dominance of
one classifier over another in ROC space implies dominance
in PR space and vice verse [43], the size of the effect can
significantly differ. In addition, PR curve has much more
natural interpretation for prioritization tasks, as it clearly shows
density of positives on the top of the prioritized list. However,
as an aggregate measure, the area under the PR curve is less
interpretable that aROC, due to unachievable regions in PR
space which size depends on class skew [44].
Only a few of manuscripts enumerated in Table II include
figures on precision, while even a smaller number show the full
PR curve. However, in contrast to sensitivity and specificity
(and consequently ROC curve) the precision (hence also PR
curve) is class balance sensitive. Therefore, reporting on these
metrics does not utilize their full descriptive potential if the
class balance of a testing set do not correspond to a class
balance that is expected in realistic use-case scenario, as
discussed in section II.B.
Finally, the argument that we made about model selection
in subsection II.B applies to the choice of performance metrics
even more. That is, using a measure that is not suitable for
assessing prioritization performance for model selection might
lead to picking a suboptimal models. For example, if a model
is selected as the best among several tested models according
to its aROC, it might not be necessary better than other tested
models in terms of aPR [43].
IV. CONCLUSION
We reviewed a portion of existing mutation prioritization
algorithms to examine the current culture of predictive per-
formance evaluation in this subfield of bioinformatics. We
discussed several issues related to ad-hoc evaluation practice,
including the choice of a testing set and performance met-
rics. In addition, we proposed various extensions of common
validation procedures that can help to mitigate the identified
problems.
We pointed out the great heterogeneity in the data sets
used for the evaluation of variant prioritization methods and
indicated where caution in interpreting the validation outcomes
should be exercised and why. Consequently, we strongly
believe that establishing a public repository, such as the UCI
database for machine learning [45], would facilitate compar-
ison of various methods and at the same time would greatly
improve consistency of benchmarking results. An noteworthy
example of work toward this goal is VariBench [46], a collec-
tion of data sets of experimentally verified variation data.
In parallel, some individual efforts towards independent as-
sessment of mutation prioritization systems have been already
undertaken (c.g., [47]). Nevertheless, we hope that community-
wide initiatives for massive prospective evaluation of compet-
ing algorithms will also take place in the near future, as it is
currently the case for protein function prediction algorithms
[48].
Furthermore, we argued that mutation prioritization is
in essence an information retrieval problem, and therefore
we suggested to supplement classical classification evaluation
metrics with their information retrieval counterparts when
evaluating novel algorithms. However, as the values of most
of these measures depend on the class distribution of the
validation set, it is essential to apply them on data where the
class balance matches the class balance expected in practice.
Fig. 2. Hypothetical mutation prioritization problem and two classifiers
used on it. Gray dots represent negative, while ”+” sign represent positive
examples. Panels A and B depict two different classification functions (solid
lines). Panels C and D depict decision boundaries corresponding to different
thresholds of the two classifiers (dotted lines). Panels E and F depict ROC
and PR curves for the two classifiers, respectively. Solid black lines with
squares represent classifier figuring on the panel B, while gray lines with
circles represent the classifier figuring on the panel A.
In this work, we restricted the discussion on the evaluation
issues associated with testing data and performance metrics.
However, other sources of potential validation problems can
be identified in the literature on mutation prioritization. For
example, not many evaluation pipelines employ statistical
testing to prove significance of differences in performance
between algorithms, even this is common practice in other
fields and appropriate guidelines have been developed [49],
[50]. Another example is the optimistic bias in performance
estimates that can result from inadequate splitting a data set
into disjoint training and testing partitions in cases when
predictive features are defined on different levels of a hierarchy
[34], [51].
Therefore, in the future we plan to conduct a comprehen-
sive review of testing procedures used for assessing the per-
formance of state-of-the-art mutation prioritization algorithms,
as well as to perform a number of simulation experiments
to better expose validation issues discussed here and other
potential problems. As a result, we hope to formalize a
complete and consistent validation framework for this type of
studies and to propose it to the research community.
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